Press Releases

XORTX Pharma Corp. Announces Grant of US Patent for the Treatment of Diabetic Nephropathy

Posted on: 15th October 2015

XORTX Pharma Corp. – a company focused on the development of drugs to treat orphan and non-orphan kidney diseases – is pleased to announce the Issuance of a U.S. Patent No. 9,155,740, entitled “COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES”. A patent with claims to the use of all uric..More

Calgary – November 28, 2014 – XORTX Pharma Corp. Announces Addition of Mr. Bruce Rowlands to the XORTX Board of Directors Board

Posted on: 28th November 2014

XORTX Pharma Corp. is pleased to announce the appointment of Mr. Bruce Rowlands to the XORTX Board of Directors, effective November 28, 2014. This appointment increases the XORTX Board of Directors to four members including Mr. Robert Reider, Mr. Bruce Rowlands, Dr. Alan Moore and Dr. Allen Davidoff – President and CEO. Mr. Rowlands has..More

Bradmer Pharmaceuticals Inc. Announces Proposed Reverse Take-Over Transaction With XORTX Pharma Corp.

Posted on: 25th November 2014

http://www.marketwired.com/press-release/bradmer-pharmaceuticals-inc-announces-proposed-reverse-take-over-transaction-with-xortx-tsx-venture-bmr.h-1969569.htm

CALGARY- July 19, 2013- XORTX Pharma Corp. Announces Election of Board Members and addition of Robert Rieder

Posted on: 19th July 2013

XORTX Pharma Corp. is pleased to announce the election of the Board of Directors, completed July 19, 2013.Election of the Board of Directors was completed by unanimous shareholder agreement and resulted in the re-election of Dr. Alan Moore and Dr. Allen Davidoff to the Board of Directors, as well as the addition of Mr. Robert..More

CALGARY- Nov 29, 2012- XORTX Pharma Corp. Announces Publication of Phase II Proof of Concept Clinical Trial in Adolescent Hypertension.

Posted on: 29th November 2012

XORTX Pharma Corp. wishes to congratulate Dr. Beth Soletsky and Dr Daniel Fieg on the successful completion of their phase II clinical trial in adolescent hypertension entitled “Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents” and publication of results in the prestigious journal Hypertension, 2012;60:1148. The trial, a randomized, double blind, placebo controlled study, was..More

CALGARY- Oct 15, 2012- XORTX Pharma Corp. Raises $450,000 in First Round Financing

Posted on: 15th October 2012

XORTX Pharma Corp. today announced the completion of a first round of financing. Dr. Allen Davidoff stated, “The company has taken a strong step forward with the completion of this first series of financing of XORTX Pharma Corp. The combination of novel patents that protect this new area of drug therapy, strong non-clinical and positive phase II..More

CALGARY- August 24, 2012- New Private Pharmaceutical Development Company Created- XORTX Pharma Corp.

Posted on: 24th August 2012

XORTX Pharma Corp. today announced the formation of a privately held Pharmaceutical Development Company built upon novel patents (intellectual property) in the fields of hypertension, insulin resistance, metabolic syndrome and diabetes prevention. The  novel patents protect the use of all uric acid lowering agents (approved and in development)  for the treatment of the aforementioned disease..More

Latest Press Releases

Archives